BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yao W, Gong W. Immunotherapy in cholangiocarcinoma: From concept to clinical trials. Surgery in Practice and Science 2021;5:100028. [DOI: 10.1016/j.sipas.2021.100028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang T, Xu C, Xu D, Yang X, Liu Y, Li X, Li Z, Dang N, Lv Y, Zhang Z, Li L, Ye K. Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.981145] [Reference Citation Analysis]
2 Kalyan A, Khosla H, Kim RD. Immunotherapy in Biliary Tract Cancers: Where Are We? Curr Oncol Rep 2022. [PMID: 36192517 DOI: 10.1007/s11912-022-01328-7] [Reference Citation Analysis]
3 Chiawpanit C, Panwong S, Sawasdee N, Yenchitsomanus P, Panya A. Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells. Biology 2022;11:1098. [DOI: 10.3390/biology11081098] [Reference Citation Analysis]
4 Scott AJ, Sharman R, Shroff RT. Precision Medicine in Biliary Tract Cancer. J Clin Oncol 2022;:JCO2102576. [PMID: 35839428 DOI: 10.1200/JCO.21.02576] [Reference Citation Analysis]
5 Trifylli E, Koustas E, Papadopoulos N, Sarantis P, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Karamouzis MV. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 2022;12:665. [DOI: 10.3390/life12050665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Oliviero B, Varchetta S, Mele D, Pessino G, Maiello R, Falleni M, Tosi D, Donadon M, Soldani C, Franceschini B, Torzilli G, Piccolo G, Barabino M, Opocher E, Maestri M, Bernuzzi S, Wucherpfennig KW, Mondelli MU, Mantovani S. MICA/B-targeted antibody promotes NK cell–driven tumor immunity in patients with intrahepatic cholangiocarcinoma. OncoImmunology 2022;11:2035919. [DOI: 10.1080/2162402x.2022.2035919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Patel A, Prashar M. ERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginning. IJMIO 2021;6:132-135. [DOI: 10.25259/ijmio_10_2021] [Reference Citation Analysis]